Cancer risk following post‐transplant lymphoproliferative disorders in solid organ transplant recipients

Post-transplant lymphoproliferative disorders (PTLDs) are associated with immunosuppressive therapy administered to prevent graft rejection, leading to uncontrolled replication of Epstein–Barr virus (EBV) (Dierickx & Habermann, 2018). Solid organ transplant (SOT) recipients also have increased risks of other malignancies, particularly those with viral aetiologies (Engels et al, 2011). In the general population, lymphoma survivors have increased...